Biofrontera Inc. (NASDAQ: BFRI) reported fourth‑quarter and full‑year 2025 financial results that marked a dramatic turnaround from the prior year. Revenue rose to $17.1 million in Q4, a 36 % increase from the same quarter in 2024, and $41.7 million for the full year, up 12 % from 2024. Net income swung to $5.6 million from a $1.4 million loss, while adjusted EBITDA reached $4.9 million versus a $1.4 million loss in 2024.
The revenue growth was driven largely by strong demand for the Ameluz photodynamic therapy platform, which continued to gain traction among dermatologists. The company’s revenue estimate of $17.29 million was narrowly missed by $0.19 million, a 1.1 % shortfall, but the overall year‑over‑year increase reflects a solid expansion of the product’s market share.
Gross profit margin expanded to 82.4 % in Q4 from 58.0 % in the prior year quarter, a result of the October 2025 acquisition that replaced a 25‑35 % transfer‑price model with a 12‑15 % royalty structure. The lower royalty cost has materially improved the company’s cost of goods sold profile, enabling higher operating leverage and setting the stage for sustained margin growth.
Management highlighted that the full‑year benefit of the new cost structure is expected to materialize in 2026, positioning Biofrontera for cash‑flow breakeven that year. The company’s cash balance stood at $6.4 million as of December 31 2025, providing a buffer for ongoing investments in the pipeline while the company scales its commercial operations.
Biofrontera’s pipeline continues to advance, with positive Phase 2b acne results, Phase 3 actinic keratoses data, and an FDA‑accepted supplemental New Drug Application for Ameluz in superficial basal cell carcinoma. The company remains focused on expanding its dermatology portfolio while navigating regulatory, competitive, and supply‑chain headwinds, but the margin expansion and strong demand signal a resilient trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.